Maze CSBO sells 7,500 shares after option exercise

Maze Therapeutics, Inc. chief business officer Atul Dandekar reported option exercises and related share sales.

Rhea-AI Filing Summary

Maze Therapeutics, Inc. chief business officer Atul Dandekar reported option exercises and related share sales. On May 29, 2026, he exercised stock options to acquire 7,500 shares of common stock at $10.42 per share and then sold 7,500 shares in open-market transactions at a weighted average price of $26.3405 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025. After these transactions, he directly owned 24,808 shares of Maze Therapeutics common stock.

Insider Trade Summary 10b5-1

Exercise and Sale: 7,500 shares ($119K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Dandekar Atul

Role CSBO

Sold 7,500 shs ($198K)

Approx. gross sale proceeds $198K

Approx. exercise cost $78K

Approx. pre-tax spread $119K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	7,500	$0.00	$0.00
Exercise	Common Stock	7,500	$10.42	$78K
Sale	Common Stock	7,500	$26.3405	$198K

Holdings After Transaction: Stock Option (Right to Buy) — 36,643 contracts (Direct); Common Stock — 24,808 shares (Direct)

Footnotes (3)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $26.64 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.

Key Figures

Shares sold: 7,500 shares Sale price (weighted average): $26.3405 per share Sale price range: $26.03–$26.64 per share +5 more

8 metrics

Shares sold 7,500 shares Common stock sold in open market on May 29, 2026

Sale price (weighted average) $26.3405 per share Weighted average sale price for 7,500 shares on May 29, 2026

Sale price range $26.03–$26.64 per share Price range for multiple sale transactions on May 29, 2026

Options exercised 7,500 shares Common stock acquired via option exercise on May 29, 2026

Option exercise price $10.42 per share Exercise price for stock option covering 7,500 shares

Shares owned after 24,808 shares Direct Maze Therapeutics common stock holdings after transactions

10b5-1 plan adoption date September 29, 2025 Date Atul Dandekar adopted Rule 10b5-1 trading plan

Option expiration date April 11, 2031 Expiration for stock option (right to buy) exercised

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), open-market sale, +2 more

6 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The reported price in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action": "derivative exercise/conversion""

fully vested financial

"The option is fully vested. Pursuant to the terms of the reporting person's award agreement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Maze Therapeutics (MAZE) report for Atul Dandekar?

Maze Therapeutics reported that CSBO Atul Dandekar exercised options for 7,500 common shares at $10.42 and sold 7,500 shares on May 29, 2026. These trades were open-market transactions disclosed in a Form 4 insider filing.

How many Maze Therapeutics (MAZE) shares did Atul Dandekar sell and at what price?

Atul Dandekar sold 7,500 Maze Therapeutics common shares at a weighted average price of $26.3405 per share. The filing notes individual trades occurred between $26.03 and $26.64 per share in multiple open-market transactions.

Did Atul Dandekar’s Maze Therapeutics (MAZE) trades use a Rule 10b5-1 plan?

Yes. The Form 4 states the sale was effected under a Rule 10b5-1 trading plan adopted by Atul Dandekar on September 29, 2025. Such plans pre-schedule trades, making the timing more routine rather than discretionary.

How many Maze Therapeutics (MAZE) shares does Atul Dandekar hold after these transactions?

Following the reported May 29, 2026 transactions, Atul Dandekar directly owned 24,808 shares of Maze Therapeutics common stock. This reflects his position after exercising 7,500 options and selling 7,500 shares in the open market.

What stock options did Atul Dandekar exercise in Maze Therapeutics (MAZE)?

He exercised a stock option covering 7,500 Maze Therapeutics common shares with an exercise price of $10.42 per share. The filing notes the option was fully vested, with vesting completed on March 17, 2025, and an expiration date of April 11, 2031.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dandekar Atul

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CSBO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		M(1)		7,500	A	$10.42	32,308	D
Common Stock	05/29/2026		S(1)		7,500	D	$26.3405(2)	24,808	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.42	05/29/2026		M(1)			7,500	(3)	04/11/2031	Common Stock	7,500	$0	36,643	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $26.64 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.

	/s/ Courtney Phillips, as attorney-in-fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)